- Home
- DXR
as 06-27-2025 12:31pm EST
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
| Founded: | 1970 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 36.4M | IPO Year: | N/A |
| Target Price: | $25.00 | AVG Volume (30 days): | 5.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.11 | EPS Growth: | 86.16 |
| 52 Week Low/High: | $6.55 - $10.00 | Next Earning Date: | 01-01-0001 |
| Revenue: | $119,714 | Revenue Growth: | -26.75% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Daxor Corporation (DXR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Feldschuh Michael Richard | DXR | Chief Executive Officer | Apr 4 '25 | Buy | $7.89 | 2,063 | $16,277.07 | 212,694 |
Latest Daxor Corporation News
DXR Breaking Stock News: Dive into DXR Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal
GlobeNewswire
2 months ago
Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems
GlobeNewswire
2 months ago
Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology
GlobeNewswire
2 months ago
Three New Medical Centers Adopt Daxor's Blood Volume Diagnostic Signaling Growing Clinical Acceptance
GlobeNewswire
2 months ago
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
GlobeNewswire
2 months ago
Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025
GlobeNewswire
2 months ago
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival
GlobeNewswire
3 months ago
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer
Compare DXR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DXR Daxor Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.